Gabriel Helmlinger
Overview
Explore the profile of Gabriel Helmlinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
797
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ugolkov Y, Nikitich A, Leon C, Helmlinger G, Peskov K, Sokolov V, et al.
Front Immunol
. 2025 Feb;
16:1557929.
PMID: 39949766
[This corrects the article DOI: 10.3389/fimmu.2024.1371620.].
2.
Kulesh V, Peskov K, Helmlinger G, Bocharov G
Front Immunol
. 2025 Feb;
16:1475871.
PMID: 39931065
Objective: To evaluate and quantitatively describe age-dependent homeostasis for a broad range of total T-cells and specific T-lymphocyte subpopulations in healthy human subjects. Methods: A systematic literature review was performed...
3.
Kudryashova N, Shulgin B, Katuninks N, Kulesh V, Helmlinger G, Zhudenkov K, et al.
Comput Struct Biotechnol J
. 2024 Oct;
24:611-621.
PMID: 39417203
We present a meta-analytics approach to quantify NSCLC disease burden by integrative survival models. Aggregated survival data from public sources were used to parameterize the models for early as well...
4.
Lim Y, Ryu I, Jung Y, Helmlinger G, Kim I, Park H, et al.
Mol Ther Nucleic Acids
. 2024 Oct;
35(4):102340.
PMID: 39411247
l-Type amino acid transporter 1 (LAT1)-specific ligands and polyion complexes are used as brain-specific targets to deliver RNA-based drugs across the blood-brain barrier. We characterized an LAT1-targeting antisense oligonucleotide (ASO)-encapsulated...
5.
Nikitich A, Helmlinger G, Peskov K, Bocharov G
Front Immunol
. 2024 Jun;
15:1357706.
PMID: 38846946
Introduction: In vivo T cell migration has been of interest to scientists for the past 60 years. T cell kinetics are important in the understanding of the immune response to...
6.
Ugolkov Y, Nikitich A, Leon C, Helmlinger G, Peskov K, Sokolov V, et al.
Front Immunol
. 2024 Mar;
15:1371620.
PMID: 38550585
The research & development (R&D) of novel therapeutic agents for the treatment of autoimmune diseases is challenged by highly complex pathogenesis and multiple etiologies of these conditions. The number of...
7.
Kulesh V, Peskov K, Helmlinger G, Bocharov G
Front Immunol
. 2024 Mar;
15:1321309.
PMID: 38469297
Background: The thymus plays a central role in shaping human immune function. A mechanistic, quantitative description of immune cell dynamics and thymic output under homeostatic conditions and various patho-physiological scenarios...
8.
Volkova A, Shulgin B, Helmlinger G, Peskov K, Sokolov V
Front Cardiovasc Med
. 2024 Feb;
10:1242845.
PMID: 38304061
Aims: To develop a model-informed methodology for the optimization of the Major Adverse Cardiac Events (MACE) composite endpoint, based on a model-based meta-analysis across anti-hypercholesterolemia trials of statin and anti-PCSK9...
9.
Zhudenkov K, Gavrilov S, Sofronova A, Stepanov O, Kudryashova N, Helmlinger G, et al.
CPT Pharmacometrics Syst Pharmacol
. 2022 Jan;
11(4):425-437.
PMID: 35064957
Clinical trials investigate treatment endpoints that usually include measurements of pharmacodynamic and efficacy biomarkers in early-phase studies and patient-reported outcomes as well as event risks or rates in late-phase studies....
10.
Voronova V, Peskov K, Kosinsky Y, Helmlinger G, Chu L, Borodovsky A, et al.
Front Immunol
. 2021 Mar;
12:617316.
PMID: 33737925
Background: Adenosine receptor type 2 (AR) inhibitor, AZD4635, has been shown to reduce immunosuppressive adenosine effects within the tumor microenvironment (TME) and to enhance the efficacy of checkpoint inhibitors across...